Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday

Verve Therapeutics (NASDAQ:VERV) is anticipated to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Verve Therapeutics to post earnings of ($0.72) per share for the quarter.

Verve Therapeutics Price Performance

Verve Therapeutics stock opened at $8.58 on Tuesday. Verve Therapeutics has a 1-year low of $4.30 and a 1-year high of $19.34. The business has a fifty day moving average price of $6.66 and a 200-day moving average price of $5.91.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright decreased their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada lowered their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.